Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02231281
Other study ID # 2014ZX10001002-001
Secondary ID 2014ZX10001002-0
Status Active, not recruiting
Phase Phase 3
First received August 26, 2014
Last updated April 24, 2018
Start date August 2014
Est. completion date December 2018

Study information

Verified date April 2018
Source Tang-Du Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the ability of the early initiation of cART or cART in combination with autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion to achieve a post-treatment control among treatment-naïve acute HIV-infected adults.


Description:

Although combined antiretroviral therapy (cART) can suppress HIV-1 replication to a very low level in the blood, but it cannot eliminate latent viral reservoirs, and need lifelong adherence to expensive regimens that have potential side effects. Increasing evidence indicates that early antiretroviral therapy for recently HIV-infected patients results in slower progression of HIV disease and represent a unique opportunity to interfere with either the quantities or qualities of persistent reservoirs of replication-competent virus. However, the time course before the interruption of cART is unclear. This study will compare the virological and immunological outcomes and HIV latency of recently infected adults who receive cART or cART in combination with autologous HIV-1 CTL infusion for different periods.

The study will last 120 weeks. Participants will be randomly assigned to either the cART or the cART plus autologous HIV-1 CTL infusion arm of one of three cohorts. The three cohorts will differ in the period of cART given. Cohort 1, Cohort 2 or Cohort 3 will receive cART (Zidovudine (AZT)/Tenofovir disoproxil fumarate (TDF) +Lamivudine (3TC) + Lopinavir / Ritonavir (LPV/r)) for 48, 72 or 96 weeks, respectively. After 48, 72 or 96 weeks, cART will be interrupted respectively. Study visits will occur at study entry, Week 4 and 12, and every 12 weeks thereafter through treatment interruption, then every 4 weeks through 12 weeks later, then every 12 weeks through Week 120. At each study visit, a physical exam, blood collection, and completion of an adherence questionnaire will occur. Clinical, virological, and immunological evaluations and HIV latency examination will be performed at most study visit.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 65
Est. completion date December 2018
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Diagnosis of acute HIV infection (meets one of following criteria)

1. Negative for anti-HIV test formerly, but with an anti-HIV serological conversion within 6 months

2. Detection of plasma HIV RNA by RT-PCR in the absence of HIV antibody

3. Low-level of anti-HIV for BED HIV-1 capture enzyme immuno assay (BED-CEIA), optical density (OD)<0.6, only for B subtype)

4. Uncertain for an anti-HIV test, with an increasing anti-HIV level for repeated test within two weeks

5. A patient with a report of recent risk behavior in association with symptoms and signs of the acute retroviral syndrome, as well as a positive for HIV antigen detection and less than 4 bands in a Western blot assay

2. Ability, willingness to give informed consent

3. Able, willing to adhere to therapy and adherent to ART

4. Able, willing to comply with time requirements for study visits and evaluations

Exclusion Criteria:

1. Chronic HIV - 1 infection

2. Any evidence of an active AIDS-defining opportunistic infection

3. Screening detects the following results:HGB<90g/L?WBC< 2 x 10E9/L?PLT< 75 x 10E9/L?hemodiastase>2 x ULN?Scr>1.5 x ULN?ALT/AST/ALP> 3 xULN?TbiL>2 xULN?CK>2 xULN?CCr<60ml/min

4. A personal history of clinically significant cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de points

5. History of chronic kidney disease

6. History of malignancy or transplantation, including skin cancers or Kaposi sarcoma

7. History of Severe peptic ulcer

8. History of alcoholism and drug abuse

9. Receipt of immunomodulating agents, immunization or systemic chemotherapeutic agents within 28 days prior to screening

10. Women who are pregnant or breastfeeding, or with a positive pregnancy test during screening or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period

11. Have contraindications to cART

12. Other condition that does not fit to participate in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cART(TDF/AZT+3TC+LPV/r)
Standard antiretroviral therapy for HIV infection
Procedure:
CTL infusion
cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion

Locations

Country Name City State
China Beijing You'an Hospital, Capital Medical University Beijing Beijing
China National Center for STD and AIDS Control and Prevention, Chinese Center for Disease Control and Prevention Beijing Beijing
China Zhejiang University Hangzhou Zhejiang
China Shandong Center for Disease Control and Prevention Jinan Shandong
China The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi
China China Medical University Shenyang Liaoning
China Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical Universit Xi'an Shaanxi

Sponsors (8)

Lead Sponsor Collaborator
Yongtao Sun, MD, PhD Beijing YouAn Hospital, China Medical University, China, First Affiliated Hospital of Guangxi Medical University, National Center for AIDS/STD Control and Prevention, China CDC, Shandong Province Centers for Disease Control and Prevention, Tang-Du Hospital, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in HIV DNA quantification at the interruption of cART HIV DNA detection includes total HIV DNA, integrated HIV DNA , 2-long terminal repeat (LTR) HIV DNA in resting CD4+T cell subsets. 48 weeks for Cohort 1, 72 weeks for Cohort 2, 96 weeks for Cohort 3
Primary Number of patients who achieve virological remission Virological remission is defined as undetectable of plasma HIV RNA for 24 weeks after the interruption of cART. 72 weeks for Cohort 1, 96 weeks for Cohort 2, 120 weeks for Cohort 3
Secondary Number of patients who occur any grade 3 or 4 (clinical or laboratory) adverse events 120 weeks
Secondary Number of patients who need to initiate late treatment Late treatment is defined cART should be administered according to local HIV treatment guidelines. 120 weeks
Secondary Time from cART interruption to virological relapse (plasma viral load more than 50 copies/mL) 120 weeks
Secondary HIV-1 specific CD4+ and CD8+ T cell responses at week 120 120 weeks
See also
  Status Clinical Trial Phase
Completed NCT02384395 - Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection N/A
Completed NCT00734344 - Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection N/A
Completed NCT01434706 - Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection N/A
Active, not recruiting NCT03711253 - Empiric Treatment for Acute HIV in the ED Phase 4
Completed NCT01154673 - Intense Acute Infection Study Phase 2/Phase 3
Terminated NCT00855413 - HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine Phase 4
Completed NCT02467439 - Acute Partner and Social Contact Referral: iKnow N/A
Not yet recruiting NCT05719441 - A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission Phase 2
Completed NCT03579381 - Specimen Repository for HIV Immunopathogenesis
Completed NCT01369056 - HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence N/A
Completed NCT02170246 - Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection Phase 1
Completed NCT02475915 - Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection Phase 1/Phase 2
Completed NCT02750059 - Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis Phase 2
Completed NCT02470351 - Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS N/A
Completed NCT00924898 - Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) Phase 4
Completed NCT02614950 - Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection N/A
Completed NCT01197027 - Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection Phase 3
Recruiting NCT05728996 - Netherlands Cohort Study on Acute HIV Infection
Recruiting NCT00796146 - Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
Recruiting NCT00796263 - Antiretroviral Therapy for Acute and Chronic HIV Infection Phase 3